Prospective Study With Adjunctive Once Daily Topical Nepafenac 0.3% Versus Placebo

NCT03025945 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

662

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystoid Macular Edema

Interventions

DRUG: Nepafenac 0.3%
DRUG: Saline Solution

Sponsor

Intuor Technologies, Inc.